The first prediction tool of its kind for early-stage classic Hodgkin lymphoma provides estimates using continuous variables capturing nonlinear context.

Hemoglobin SS (HbSS) Around 65 percent of people with sickle cell disease have HbSS, a severe type. People with HbSS inherit an abnormal gene connected to hemoglobin production, hemoglobin S, from ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.